{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T13:26:06Z","timestamp":1768051566662,"version":"3.49.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T00:00:00Z","timestamp":1763942400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Health Holland TKI subsidy","award":["project n. EMCLSHPC24044"],"award-info":[{"award-number":["project n. EMCLSHPC24044"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1007\/s40259-025-00757-7","type":"journal-article","created":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T05:53:20Z","timestamp":1763963600000},"page":"163-173","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Can Alpha-Glucosidase Activity in Plasma or Leukocytes Serve as a Biomarker for Future Gene Therapy in Classic Infantile Pompe Disease?"],"prefix":"10.1007","volume":"40","author":[{"given":"Martha C.","family":"Faraguna","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dani\u00ebl A.M.","family":"Lambregts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ina","family":"Barzel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ed H.","family":"Jacobs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Hoogeveen-Westerveld","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadine A. M. E.","family":"van der Beek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. W. M. Pim","family":"Pijnappel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serena","family":"Gasperini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tim","family":"Preijers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8091-263X","authenticated-orcid":false,"given":"Johanna M. P.","family":"van den Hout","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ans T.","family":"van der Ploeg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,24]]},"reference":[{"key":"757_CR1","doi-asserted-by":"publisher","DOI":"10.1002\/humu.24148","author":"DOS de Faria","year":"2021","unstructured":"de Faria DOS, t Groen S, Hoogeveen-Westerveld M, Nino MY, van der Ploeg AT, Bergsma AJ, et al. Update of the Pompe variant database for the prediction of clinical phenotypes: novel disease-associated variants, common sequence variants, and results from newborn screening. Hum Mutat. 2021;42(2):119-134. https:\/\/doi.org\/10.1002\/humu.24148.","journal-title":"Hum Mutat"},{"key":"757_CR2","doi-asserted-by":"publisher","DOI":"10.1038\/s41431-020-00752-2","author":"MY Ni\u00f1o","year":"2021","unstructured":"Ni\u00f1o MY, Wijgerde M, de Faria DOS DOS, Hoogeveen-Westerveld M, Bergsma AJ, Broeders M, et al. Enzymatic diagnosis of Pompe disease: lessons from 28 years of experience. Eur J Hum Genet. 2021;29(3):434-446. https:\/\/doi.org\/10.1038\/s41431-020-00752-2.","journal-title":"Eur J Hum Genet"},{"key":"757_CR3","doi-asserted-by":"publisher","DOI":"10.1542\/peds.112.2.332","author":"HMP den Van Hout","year":"2003","unstructured":"den Van Hout HMP, Hop W, Van Diggelen OP, Smeitink JAM, Smit GPA, Poll-The BTT, et al. The natural course of infantile Pompe\u2019s disease: 20 original cases compared with 133 cases from the literature. Pediatrics. 2003;112(2):332-340. https:\/\/doi.org\/10.1542\/peds.112.2.332.","journal-title":"Pediatrics"},{"issue":"1","key":"757_CR4","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1186\/s13023-020-01482-w","volume":"15","author":"JJA van den Dorpel","year":"2020","unstructured":"van den Dorpel JJA, Poelman E, Harlaar L, van Kooten HA, van der Giessen LJ, van Doorn PA, et al. Distal muscle weakness is a common and early feature in long-term enzyme-treated classic infantile Pompe patients. Orphanet J Rare Dis. 2020;15(1):247. https:\/\/doi.org\/10.1186\/s13023-020-01482-w.","journal-title":"Orphanet J Rare Dis"},{"issue":"13","key":"757_CR5","doi-asserted-by":"publisher","first-page":"283","DOI":"10.21037\/atm.2019.04.70","volume":"7","author":"A Hahn","year":"2019","unstructured":"Hahn A, Schanzer A. Long-term outcome and unmet needs in infantile-onset Pompe disease. Ann Transl Med. 2019;7(13):283\u2013283. https:\/\/doi.org\/10.21037\/atm.2019.04.70.","journal-title":"Ann Transl Med"},{"issue":"9","key":"757_CR6","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gim.2012.44","volume":"14","author":"SN Prater","year":"2012","unstructured":"Prater SN, Banugaria SG, DeArmey SM, Botha EG, Stege EM, Case LE, et al. The emerging phenotype of long-term survivors with infantile Pompe disease. Genet Med. 2012;14(9):800\u201310. https:\/\/doi.org\/10.1038\/gim.2012.44.","journal-title":"Genet Med"},{"key":"757_CR7","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000207482","author":"MJ Mackenbach","year":"2023","unstructured":"Mackenbach MJ, Willemse EAJ, van den Dorpel JJA, van der Beek N, Diaz-Manera J, Rizopoulos D, et al. Neurofilament light and its association with CNS involvement in patients with classic infantile Pompe disease. Neurology. 2023;101(6):e594-e601. https:\/\/doi.org\/10.1212\/WNL.0000000000207482.","journal-title":"Neurology"},{"issue":"4","key":"757_CR8","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1002\/jimd.12736","volume":"47","author":"JJA van den Dorpel","year":"2024","unstructured":"van den Dorpel JJA, Mackenbach MJ, Dremmen MHG, van der Vlugt WMC, Rizopoulos D, van Doorn PA, et al. Long term survival in patients with classic infantile Pompe disease reveals a spectrum with progressive brain abnormalities and changes in cognitive functioning. J Inherit Metab Dis. 2024;47(4):716\u201330. https:\/\/doi.org\/10.1002\/jimd.12736.","journal-title":"J Inherit Metab Dis"},{"issue":"2","key":"757_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymgme.2023.108119","volume":"141","author":"D Kenney-Jung","year":"2024","unstructured":"Kenney-Jung D, Korlimarla A, Spiridigliozzi GA, Wiggins W, Malinzak M, Nichting G, et al. Severe CNS involvement in a subset of long-term treated children with infantile-onset Pompe disease. Mol Genet Metab. 2024;141(2):108119. https:\/\/doi.org\/10.1016\/j.ymgme.2023.108119.","journal-title":"Mol Genet Metab"},{"issue":"2","key":"757_CR10","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.ymgme.2017.04.014","volume":"121","author":"GA Spiridigliozzi","year":"2017","unstructured":"Spiridigliozzi GA, Keeling LA, Stefanescu M, Li C, Austin S, Kishnani PS. Cognitive and academic outcomes in long-term survivors of infantile-onset Pompe disease: a longitudinal follow-up. Mol Genet Metab. 2017;121(2):127\u201337. https:\/\/doi.org\/10.1016\/j.ymgme.2017.04.014.","journal-title":"Mol Genet Metab"},{"key":"757_CR11","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.omtm.2022.09.010","volume":"27","author":"Q Liang","year":"2022","unstructured":"Liang Q, Catalano F, Vlaar EC, Pijnenburg JM, Stok M, van Helsdingen Y, et al. IGF2-tagging of GAA promotes full correction of murine Pompe disease at a clinically relevant dosage of lentiviral gene therapy. Mol Ther Methods Clin Dev. 2022;27:109\u201330. https:\/\/doi.org\/10.1016\/j.omtm.2022.09.010.","journal-title":"Mol Ther Methods Clin Dev"},{"key":"757_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jprot.2023.105037","volume":"291","author":"Q Liang","year":"2024","unstructured":"Liang Q, Vlaar EC, Pijnenburg JM, Rijkers E, Demmers JAA, Vulto AG, et al. Lentiviral gene therapy with IGF2-tagged GAA normalizes the skeletal muscle proteome in murine Pompe disease. J Proteomics. 2024;291:105037. https:\/\/doi.org\/10.1016\/j.jprot.2023.105037.","journal-title":"J Proteomics"},{"issue":"7","key":"757_CR13","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1016\/j.ymthe.2023.02.014","volume":"31","author":"EC Smith","year":"2023","unstructured":"Smith EC, Hopkins S, Case LE, Xu M, Walters C, Dearmey S, et al. Phase I study of liver depot gene therapy in late-onset Pompe disease. Mol Ther. 2023;31(7):1994\u20132004. https:\/\/doi.org\/10.1016\/j.ymthe.2023.02.014.","journal-title":"Mol Ther"},{"issue":"3","key":"757_CR14","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s10545-015-9912-y","volume":"39","author":"CM van Gelder","year":"2016","unstructured":"van Gelder CM, Poelman E, Plug I, Hoogeveen-Westerveld M, van der Beek NAME, Reuser AJJ, et al. Effects of a higher dose of alglucosidase alfa on ventilator-free survival and motor outcome in classic infantile Pompe disease: an open-label single-center study. J Inherit Metab Dis. 2016;39(3):383\u201390. https:\/\/doi.org\/10.1007\/s10545-015-9912-y.","journal-title":"J Inherit Metab Dis"},{"issue":"4","key":"757_CR15","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.ymgme.2010.08.009","volume":"101","author":"JM de Vries","year":"2010","unstructured":"de Vries JM, van der Beek NAME, Kroos MA, \u00d6zkan L, van Doorn PA, Richards SM, et al. High antibody titer in an adult with Pompe disease affects treatment with alglucosidase alfa. Mol Genet Metab. 2010;101(4):338\u201345. https:\/\/doi.org\/10.1016\/j.ymgme.2010.08.009.","journal-title":"Mol Genet Metab"},{"key":"757_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s10545-009-1082-3","author":"OP Diggelen","year":"2009","unstructured":"Diggelen OP, Oemardien LF, van der Beek NAME, Kroos MA, Wind HK, Voznyi YV, et al. Enzyme analysis for Pompe disease in leukocytes; superior results with natural substrate compared with artificial substrates. J Inherit Metab Di. 2009;32(3):416-423. https:\/\/doi.org\/10.1007\/s10545-009-1082-3.","journal-title":"J Inherit Metab Di"},{"key":"757_CR17","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.jpeds.2017.11.046","volume":"195","author":"E Poelman","year":"2018","unstructured":"Poelman E, Hoogeveen-Westerveld M, de Kroos- Haan MA, van den Hout JMP, Bronsema KJ, van de Merbel NC, et al. High sustained antibody titers in patients with classic infantile Pompe disease following immunomodulation at start of enzyme replacement therapy. J Pediatr. 2018;195:236-243.e3. https:\/\/doi.org\/10.1016\/j.jpeds.2017.11.046.","journal-title":"J Pediatr"},{"key":"757_CR18","doi-asserted-by":"publisher","DOI":"10.1007\/s10928-015-9432-2","author":"S William","year":"2015","unstructured":"William S, Denney SD, Buckeridge C. Simple, automatic noncompartmental analysis: the PKNCA R package. J Pharmacokinet Pharmacodyn. 2015;42(1):11-107. https:\/\/doi.org\/10.1007\/s10928-015-9432-2.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"757_CR19","unstructured":"European Medicines Agency. Summary of Product Characteristics: Myozyme. Available from: https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/myozyme. Accessed 2 Oct 2024."},{"key":"757_CR20","unstructured":"Street K. Myozyme\u00ae (alglucosidase alfa): final report study number AGLU02403. 2007."},{"key":"757_CR21","doi-asserted-by":"publisher","DOI":"10.1016\/j.nmd.2018.12.004","author":"LDM Pena","year":"2019","unstructured":"Pena LDM, Barohn RJ, Byrne BJ, Desnuelle C, Goker-Alpan O, Ladha S, et al. Safety, tolerability, pharmacokinetics, pharmacodynamics, and exploratory efficacy of the novel enzyme replacement therapy avalglucosidase alfa (neoGAA) in treatment-naive and alglucosidase alfa-treated patients with late-onset Pompe disease: a phase 1, open-label, multicenter, multinational, ascending dose study. Neuromuscul Disord. 2019;29(3):167-186. https:\/\/doi.org\/10.1016\/j.nmd.2018.12.004.","journal-title":"Neuromuscul Disord"},{"issue":"2","key":"757_CR22","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1172\/JCI115025","volume":"87","author":"AT der Van Ploeg","year":"1991","unstructured":"der Van Ploeg AT, Kroos MA, Willemsen R, Brons NH, Reuser AJ. Intravenous administration of phosphorylated acid alpha-glucosidase leads to uptake of enzyme in heart and skeletal muscle of mice. J Clin Invest. 1991;87(2):513\u20138. https:\/\/doi.org\/10.1172\/JCI115025.","journal-title":"J Clin Invest"},{"issue":"12","key":"757_CR23","doi-asserted-by":"publisher","first-page":"2145","DOI":"10.1093\/hmg\/8.12.2145","volume":"8","author":"AGA Bijvoet","year":"1999","unstructured":"Bijvoet AGA, Van Hirtum H, Kroos MA, Van De Kamp EHM, Schoneveld O, Visser P, et al. Human acid \u03b1-glucosidase from rabbit milk has therapeutic effect in mice with glycogen storage disease type II. Hum Mol Genet. 1999;8(12):2145\u201353. https:\/\/doi.org\/10.1093\/hmg\/8.12.2145.","journal-title":"Hum Mol Genet"},{"key":"757_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2004.09.017","author":"N Raben","year":"2005","unstructured":"Raben N, Fukuda T, Gilbert AL, de Jong D, Thurberg RJ, Mattaliano P, et al. Replacing acid alpha-glucosidase in Pompe disease: recombinant and transgenic enzymes are equipotent, but neither completely clears glycogen from type II muscle fibers. Mol Ther. 2005;11(1):48-56. https:\/\/doi.org\/10.1016\/j.ymthe.2004.09.017.","journal-title":"Mol Ther"},{"issue":"3","key":"757_CR25","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1007\/s10545-011-9285-9","volume":"34","author":"XS Zhang","year":"2011","unstructured":"Zhang XS, Brondyk W, Lydon JT, Thurberg BL, Piepenhagen PA. Biotherapeutic target or sink: analysis of the macrophage mannose receptor tissue distribution in murine models of lysosomal storage diseases. J Inherit Metab Dis. 2011;34(3):795\u2013809. https:\/\/doi.org\/10.1007\/s10545-011-9285-9.","journal-title":"J Inherit Metab Dis"},{"issue":"7","key":"757_CR26","doi-asserted-by":"publisher","first-page":"4597","DOI":"10.1074\/jbc.M210612200","volume":"278","author":"EI Park","year":"2003","unstructured":"Park EI, Manzella SM, Baenziger JU. Rapid clearance of sialylated glycoproteins by the asialoglycoprotein receptor. J Biol Chem. 2003;278(7):4597\u2013602. https:\/\/doi.org\/10.1074\/jbc.M210612200.","journal-title":"J Biol Chem"},{"key":"757_CR27","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2014.00177","author":"JA Lim","year":"2014","unstructured":"Lim JA, Li L, Raben N. Pompe disease: from pathophysiology to therapy and back again. Front Aging Neurosci. 2014;6:177. https:\/\/doi.org\/10.3389\/fnagi.2014.00177.","journal-title":"Front Aging Neurosci"},{"issue":"8","key":"757_CR28","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/s0962-8924(00)01794-3","volume":"10","author":"NW Andrews","year":"2000","unstructured":"Andrews NW. Regulated secretion of conventional lysosomes. Trends Cell Biol. 2000;10(8):316\u201321. https:\/\/doi.org\/10.1016\/s0962-8924(00)01794-3.","journal-title":"Trends Cell Biol"},{"key":"757_CR29","doi-asserted-by":"publisher","DOI":"10.3390\/membranes10120406","author":"B Tancini","year":"2020","unstructured":"Tancini B, Buratta S, Delo F, Sagini K, Chiaradia E, Pellegrino RM, et al. Lysosomal exocytosis: the extracellular role of an intracellular organelle. Membranes (Basel). 2020;10(12):406. https:\/\/doi.org\/10.3390\/membranes10120406.","journal-title":"Membranes (Basel)."},{"key":"757_CR30","unstructured":"The Human Protein Atlas. Insulin like growth factor 2 receptor. Available from: https:\/\/www.proteinatlas.org\/ENSG00000197081-IGF2R. Accessed 13 Jan 2025."},{"issue":"2","key":"757_CR31","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s10545-009-9027-4","volume":"33","author":"ML Hagemans","year":"2010","unstructured":"Hagemans ML, Stigter RL, van Capelle CI, van der Beek NA, Winkel LP, van Vliet L, et al. PAS-positive lymphocyte vacuoles can be used as diagnostic screening test for Pompe disease. J Inherit Metab Dis. 2010;33(2):133\u20139. https:\/\/doi.org\/10.1007\/s10545-009-9027-4.","journal-title":"J Inherit Metab Dis"},{"key":"757_CR32","doi-asserted-by":"publisher","DOI":"10.7156\/najms.2013.0604186","author":"C Yu","year":"2013","unstructured":"Yu C, Sun Q, Zhou H. Enzymatic screening and diagnosis of lysosomal storage diseases. North Am J Med Sci. 2013;6(4):186-193. https:\/\/doi.org\/10.7156\/najms.2013.0604186.","journal-title":"North Am J Med Sci."},{"key":"757_CR33","unstructured":"Mayes JS, Cray EL, Dell VA, Scheerer JB, Sifers RN. Endocytosis of lysosomal alpha-galactosidase A by cultured fibroblasts from patients with Fabry disease. Am J Hum Genet. 1982;34(4):602-10."},{"issue":"6","key":"757_CR34","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1002\/mus.10381","volume":"27","author":"LPF Winkel","year":"2003","unstructured":"Winkel LPF, Kamphoven JHJ, Van Den Hout HJMP, Severijnen LA, Van Doorn PA, Reuser AJJ, et al. Morphological changes in muscle tissue of patients with infantile Pompe\u2019s disease receiving enzyme replacement therapy. Muscle Nerve. 2003;27(6):743\u201351. https:\/\/doi.org\/10.1002\/mus.10381.","journal-title":"Muscle Nerve"},{"issue":"3","key":"757_CR35","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/0022-510x(87)90239-5","volume":"79","author":"AT van der Ploeg","year":"1987","unstructured":"van der Ploeg AT, Kroos M, van Dongen JM, Visser WJ, Bolhuis PA, Loonen MC, et al. Breakdown of lysosomal glycogen in cultured fibroblasts from glycogenosis type II patients after uptake of acid alpha-glucosidase. J Neurol Sci. 1987;79(3):327\u201336. https:\/\/doi.org\/10.1016\/0022-510x(87)90239-5.","journal-title":"J Neurol Sci"}],"updated-by":[{"DOI":"10.1007\/s40259-025-00760-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000}}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-025-00757-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-025-00757-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T07:13:21Z","timestamp":1768029201000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-025-00757-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,24]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["757"],"URL":"https:\/\/doi.org\/10.1007\/s40259-025-00757-7","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,24]]},"assertion":[{"value":"9 November 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2025","order":4,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":5,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The author\u2019s name W. W. M. Pim Pijnappel was\nincorrectly written as Pim W. W. M. Pijnappel.","order":6,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2025","order":7,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":8,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":9,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s40259-025-00760-y","URL":"https:\/\/doi.org\/10.1007\/s40259-025-00760-y","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ans T. van der Ploeg and Johanna M.P. van den Hout received funding for research, clinical trials, and\/or as an advisor from various industries working on ERT or next-generation therapies in the field of Pompe disease under agreements with Erasmus MC University Medical Center and the relevant industry. Pim W.W.M. Pijnappel is a co-founder and unpaid Chief Scientific Officer of LentiCure, a company developing gene therapy for lysosomal disorders including Pompe disease. Nadine A.M.E van der Beek has received consulting fees for advisory boards or speaker honoraria from Sanofi, Amicus Therapeutics, Shionogi, and Bayer under agreements with Erasmus MC University Medical Center and the relevant industry. Ed H. Jacobs and Marianne Hoogeveen-Westerveld received funding for clinical trial and contract work from Spark Therapeutics and Amicus Therapeutics. Martha C. Faraguna, Daan Lambregts, Ina Barzel, Serena Gasperini, and Tim Preijers have no conflicts of interest that are directly relevant to the content of this article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest\/Competing Interests"}},{"value":"Patients with Pompe disease followed at the Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center in Rotterdam, the Netherlands are enrolled in the prospective protocol MEC-2007-103-NL, approved by the Medical Ethical Committee of Erasmus Medical Center.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Patients or their parents\/legal guardians provided written consent to participate in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Patients or their parents\/legal guardians consented to publication of this study.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All original data are present in the article. Further enquiries can be addressed to the corresponding author.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Enquiries concerning the code can be addressed to the corresponding author.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"MCF participated in planning the project and design of experiments, collected data, analyzed and interpreted data. and wrote the draft of the manuscript. ATP and JMPH conceived the project, designed experiments, interpreted data, participated in discussions, and edited several versions of this manuscript. IB and TP contributed to the PK analysis, results interpretation, improvement of figure quality, and reviewed several versions of the paper. DL, SG, PWWMP, and NAME participated in data interpretation and reviewed several drafts of the manuscript. EHJ and MHW supervised enzyme activity measurement and the enzyme-linked immunosorbent assay, analyzed and interpreted data, and contributed to the manuscript preparation.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}